YD Bio (YDES) Competitors

YD Bio logo
$4.73 -0.10 (-2.07%)
Closing price 04:00 PM Eastern
Extended Trading
$4.59 -0.14 (-3.04%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

YDES vs. SLS, NVAX, NBTX, IMCR, and RARE

Should you buy YD Bio stock or one of its competitors? YD Bio's main competitors and comparable companies include SELLAS Life Sciences Group (SLS), Novavax (NVAX), Nanobiotix (NBTX), Immunocore (IMCR), and Ultragenyx Pharmaceutical (RARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does YD Bio compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, SELLAS Life Sciences Group had 37 more articles in the media than YD Bio. MarketBeat recorded 40 mentions for SELLAS Life Sciences Group and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.62 beat SELLAS Life Sciences Group's score of 0.22 indicating that YD Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
6 Very Positive mention(s)
7 Positive mention(s)
15 Neutral mention(s)
6 Negative mention(s)
2 Very Negative mention(s)
Neutral
YD Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market. Comparatively, YD Bio has a beta of -1.2, suggesting that its stock price is 220% less volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, indicating a potential downside of 47.78%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

YD Bio's return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -31.95% -29.86%
YD Bio N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.20N/A
YD BioN/AN/AN/AN/AN/A

Summary

SELLAS Life Sciences Group beats YD Bio on 7 of the 10 factors compared between the two stocks.

How does YD Bio compare to Novavax?

YD Bio (NASDAQ:YDES) and Novavax (NASDAQ:NVAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Novavax has a consensus price target of $12.33, indicating a potential upside of 54.94%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Novavax
3 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.20

Novavax has higher revenue and earnings than YD Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
YD BioN/AN/AN/AN/AN/A
Novavax$1.12B1.17$440.30M-$0.46N/A

YD Bio has a net margin of 0.00% compared to Novavax's net margin of -18.64%. YD Bio's return on equity of 0.00% beat Novavax's return on equity.

Company Net Margins Return on Equity Return on Assets
YD BioN/A N/A N/A
Novavax -18.64%-14.82%-7.55%

53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Novavax had 1 more articles in the media than YD Bio. MarketBeat recorded 4 mentions for Novavax and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.62 beat Novavax's score of 0.56 indicating that YD Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
YD Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novavax
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

YD Bio has a beta of -1.2, meaning that its share price is 220% less volatile than the broader market. Comparatively, Novavax has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market.

Summary

Novavax beats YD Bio on 8 of the 12 factors compared between the two stocks.

How does YD Bio compare to Nanobiotix?

YD Bio (NASDAQ:YDES) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, YD Bio had 2 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for YD Bio and 1 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat YD Bio's score of 0.62 indicating that Nanobiotix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
YD Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nanobiotix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nanobiotix has a consensus target price of $46.67, indicating a potential upside of 70.01%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts plainly believe Nanobiotix is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

YD Bio has higher earnings, but lower revenue than Nanobiotix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
YD BioN/AN/AN/AN/AN/A
Nanobiotix$36.87M37.95-$27.11MN/AN/A

Company Net Margins Return on Equity Return on Assets
YD BioN/A N/A N/A
Nanobiotix N/A N/A N/A

YD Bio has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Nanobiotix beats YD Bio on 8 of the 9 factors compared between the two stocks.

How does YD Bio compare to Immunocore?

YD Bio (NASDAQ:YDES) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Immunocore has a consensus target price of $52.86, suggesting a potential upside of 90.07%. Given Immunocore's stronger consensus rating and higher probable upside, analysts plainly believe Immunocore is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Immunocore
2 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.50

YD Bio has a net margin of 0.00% compared to Immunocore's net margin of -7.48%. YD Bio's return on equity of 0.00% beat Immunocore's return on equity.

Company Net Margins Return on Equity Return on Assets
YD BioN/A N/A N/A
Immunocore -7.48%-7.96%-2.93%

84.5% of Immunocore shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

YD Bio has higher earnings, but lower revenue than Immunocore.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
YD BioN/AN/AN/AN/AN/A
Immunocore$400.02M3.58-$35.51M-$0.65N/A

YD Bio has a beta of -1.2, suggesting that its share price is 220% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

In the previous week, Immunocore had 19 more articles in the media than YD Bio. MarketBeat recorded 22 mentions for Immunocore and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.62 beat Immunocore's score of -0.08 indicating that YD Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
YD Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunocore
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Immunocore beats YD Bio on 9 of the 13 factors compared between the two stocks.

How does YD Bio compare to Ultragenyx Pharmaceutical?

YD Bio (NASDAQ:YDES) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

YD Bio has a beta of -1.2, meaning that its share price is 220% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

YD Bio has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
YD BioN/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical$673M2.53-$575M-$5.19N/A

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than YD Bio. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.62 beat Ultragenyx Pharmaceutical's score of 0.39 indicating that YD Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
YD Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ultragenyx Pharmaceutical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

YD Bio has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -71.78%.

Company Net Margins Return on Equity Return on Assets
YD BioN/A N/A N/A
Ultragenyx Pharmaceutical -71.78%N/A -39.70%

Ultragenyx Pharmaceutical has a consensus price target of $29.79, indicating a potential upside of 78.38%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

Summary

Ultragenyx Pharmaceutical beats YD Bio on 9 of the 12 factors compared between the two stocks.

Get YD Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for YDES and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YDES and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YDES vs. The Competition

MetricYD BioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$341.91M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.46%
P/E RatioN/A27.4232.3226.73
Price / SalesN/A16.068.565.71
Price / CashN/A22.9521.0121.90
Price / BookN/A4.184.463.72
Net IncomeN/A-$24.15M$3.52B$393.10M
7 Day Performance-21.56%-7.25%-5.47%-4.73%
1 Month Performance-20.10%-5.98%-4.57%-7.14%
1 Year PerformanceN/A-7.72%-1.79%-7.51%

YD Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
YDES
YD Bio
1.3723 of 5 stars
$4.73
-2.1%
N/AN/A$341.91MN/AN/A14
SLS
SELLAS Life Sciences Group
0.415 of 5 stars
$8.42
+0.6%
$10.00
+18.8%
+422.4%$1.69BN/AN/A13
NVAX
Novavax
1.9562 of 5 stars
$9.98
-2.2%
$12.33
+23.6%
+15.6%$1.68B$411.65MN/A749
NBTX
Nanobiotix
3.3745 of 5 stars
$32.95
+0.2%
$46.67
+41.6%
+37.2%$1.68B$8.36MN/A97
IMCR
Immunocore
2.4735 of 5 stars
$31.65
-2.3%
$53.00
+67.5%
-19.7%$1.67B$429.30MN/A524

Related Companies and Tools


This page (NASDAQ:YDES) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners